<?xml version="1.0" encoding="UTF-8"?>
<ref id="B113-vaccines-08-00273">
 <label>113.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bounds</surname>
    <given-names>C.E.</given-names>
   </name>
   <name>
    <surname>Terry</surname>
    <given-names>F.E.</given-names>
   </name>
   <name>
    <surname>Moise</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Hannaman</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Martin</surname>
    <given-names>W.D.</given-names>
   </name>
   <name>
    <surname>De Groot</surname>
    <given-names>A.S.</given-names>
   </name>
   <name>
    <surname>Suschak</surname>
    <given-names>J.J.</given-names>
   </name>
   <name>
    <surname>Dupuy</surname>
    <given-names>L.C.</given-names>
   </name>
   <name>
    <surname>Schmaljohn</surname>
    <given-names>C.S.</given-names>
   </name>
  </person-group>
  <article-title>An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice</article-title>
  <source>Hum. Vaccines Immunother.</source>
  <year>2017</year>
  <volume>13</volume>
  <fpage>2824</fpage>
  <lpage>2836</lpage>
  <pub-id pub-id-type="doi">10.1080/21645515.2017.1329788</pub-id>
 </element-citation>
</ref>
